New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - metformin hydrochloride 850mg;  ;  ; metformin hydrochloride 850mg - film coated tablet - 850 mg - active: metformin hydrochloride 850mg     excipient: dri-klear magnesium stearate povidone active: metformin hydrochloride 850mg excipient: magnesium stearate opadry clear 20c59060 povidone - · treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control · metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents. · adjuvant therapy in insulin dependent diabetes especially if overweight.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; hypromellose; macrogol 6000; macrogol 400 - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, children from 10 years of age and adolescents, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.,for adult patients, metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents or as adjuvant therapy in insulin requiring type 2 diabetes.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; hypromellose; macrogol 6000; macrogol 400 - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, children from 10 years of age and adolescents, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.,for adult patients, metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents or as adjuvant therapy in insulin requiring type 2 diabetes.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - metformin hydrochloride 850mg;  ;  ; metformin hydrochloride 850mg - film coated tablet - 850 mg - active: metformin hydrochloride 850mg     excipient: colloidal silicon dioxide hypromellose macrogol 6000 magnesium stearate maize starch povidone propylene glycol purified talc sodium starch glycolate titanium dioxide active: metformin hydrochloride 850mg excipient: colloidal silicon dioxide hypromellose macrogol 6000 magnesium stearate maize starch povidone propylene glycol purified talc sodium starch glycolate titanium dioxide - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - linagliptin, quantity: 2.5 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: hypromellose; purified talc; colloidal anhydrous silica; magnesium stearate; copovidone; propylene glycol; titanium dioxide; arginine; iron oxide yellow; maize starch; iron oxide red - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - linagliptin, quantity: 2.5 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: arginine; magnesium stearate; purified talc; copovidone; maize starch; iron oxide yellow; titanium dioxide; colloidal anhydrous silica; hypromellose; propylene glycol; iron oxide red - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; titanium dioxide; magnesium stearate; maize starch; propylene glycol; hypromellose; purified talc; povidone; macrogol 6000; colloidal anhydrous silica - treatment of type 2 diabetes mellitus in adults, particularly in over weight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. metformin may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; propylene glycol; hypromellose; sodium starch glycollate; maize starch; purified talc; macrogol 6000; magnesium stearate; titanium dioxide; povidone - treatment of type 2 diabetes mellitus in adults, particularly in over weight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. metformin may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - metformina hidrocloruro - comprimido recubierto con pelÍcula - 850 mg - metformina hidrocloruro 850 mg - metformina

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

viatris limited - metformina hidrocloruro - comprimido recubierto con pelÍcula - 850 mg - metformina hidrocloruro 850 mg - metformina